{
    "nct_id": "NCT03765762",
    "title": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-01-08",
    "description_brief": "This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.",
    "description_detailed": "This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and potential cognitive benefit of GRF6019, a human plasma protein fraction. GRF6019 or placebo will be administered intravenously to subjects with severe Alzheimer's disease every day for 5 consecutive days. The total study duration for each subject is approximately 9 weeks.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "GRF6019",
                    "description": "GRF6019 250 mL IV for 5 consecutive days"
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "Placebo 250 mL IV for 5 consecutive days"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "18"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "8"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "18"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "8"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "GRF6019",
                    "description": "GRF6019 250 mL IV for 5 consecutive days"
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "Placebo 250 mL IV for 5 consecutive days"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "18"
                        },
                        {
                            "groupId": "BG001",
                            "value": "8"
                        },
                        {
                            "groupId": "BG002",
                            "value": "26"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "75.2",
                                            "spread": "8.25"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "69.5",
                                            "spread": "8.12"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "73.5",
                                            "spread": "8.49"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "16"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ethnicity (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Not Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "26"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Duration of Alzheimer's Disease",
                    "description": "Years of Alzheimer's Disease Duration calculated from Medical History Year of Diagnosis to Year of Informed Consent",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "5.0",
                                            "spread": "1.81"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6.0",
                                            "spread": "3.59"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "5.3",
                                            "spread": "2.46"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Frequency of Treatment-emergent Adverse Events (Safety)",
                    "description": "Number of Subjects with at Least One Treatment-emergent adverse event by MedDRA preferred term and grouped by MedDRA System Organ Class",
                    "populationDescription": "Safety: All subjects who received any amount of study treatment",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Tolerability of GRF6019",
                    "description": "Tolerability of treatment defined by the number of subjects completing 4 weeks of study after receiving 5 daily infusions",
                    "populationDescription": "Safety: All subjects who received any amount of study treatment",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Mini-Mental State Examination (MMSE) Score",
                    "description": "Mean change from Baseline to 5 Weeks in the Mini-Mental State Examination (MMSE) score. The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language. The scores from the 5 components are summed to obtain the overall MMSE total score. The MMSE total score can range from 0 to 30, with higher scores indicating better mental status.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.3",
                                            "spread": "3.53"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.8",
                                            "spread": "3.20"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Severe Impairment Battery (SIB) Total Score",
                    "description": "Mean change from baseline in the SIB total score. The SIB assesses cognition; test questions measure orientation, attention, language, praxis, visuospatial perception, construction, memory, orientation to name, and social interaction. There are 57 items and the range of possible scores is 0-133. Lower scores indicate greater cognitive impairment.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6.7",
                                            "spread": "7.59"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.4",
                                            "spread": "4.93"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Cooperative Study Group Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-Severe)",
                    "description": "Mean change from baseline in the ADCS-ADL-Severe score. The ADCS-ADL-Severe contains 19 items covering physical and mental functioning and independence in self-care and assesses the competence in performing basic activities of daily living. The scores range from 0 to 54, with higher scores indicating less functional impairment.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.6",
                                            "spread": "5.05"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.5",
                                            "spread": "4.93"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Plus Caregiver Input (ADCS-CGIC)",
                    "description": "Mean ADCS-CGIC score. A CGIC score is based on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. The ADCS-CGIC is a rating of change and not of severity. It provides a semi structured format to enable clinicians to gather necessary clinical information from both the subject and informant to make a global impression of change. After completing the interviews, the clinician records the clinical impression of change on a 7-point Likert-type scale (from marked improvement to marked worsening). A score of 4 indicates no change, while scores \\> 4 indicate worsening and scores \\< 4 indicate improvement.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.9",
                                            "spread": "0.83"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4.0",
                                            "spread": "0.76"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory Nursing Home (NPI-NH) Total Score",
                    "description": "Mean change from Baseline to 5 weeks in the NPI-NH total score. The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains (Delusions, Hallucinations, Agitation/Aggression, Depression/Dysphoria, Anxiety, Elation/Euphoria, Apathy/Indifference, Disinhibition, Irritability/Lability, Aberrant Motor Behavior, Sleep and Nighttime Behavior Disorders, Appetite/Eating Changes). For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), with a possible summed total score of 0 to 144. Lower scores correspond to less severity. A negative change score from baseline indicates improvement.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-7.0",
                                            "spread": "19.16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-20.0",
                                            "spread": "5.66"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI) Caregiver Total Score",
                    "description": "Mean change from Baseline to 5 Weeks in NPI Total Score. NPI is based on responses from the informed caregiver during an interview. It consists of 12 sub-domains (Delusions, Hallucinations, Agitation/Aggression, Dysphoria/Depression, Anxiety, Euphoria/Elation, Apathy/Indifference, Disinhibition, Irritability/Lability, Aberrant Motor, Nighttime Behavior, Appetite/Eating). For each of the 12 behavioral domains the Distress (scale:0=Not distressing at all to 5=Extreme) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (distress x severity), with a possible summed total score of 0 to 180. Lower scores correspond to less severity. A negative change score from baseline indicates improvement.",
                    "populationDescription": "Evaluable: Subjects who received at least 4 of the 5 planned infusions",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 5 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019",
                            "description": "GRF6019 250 mL IV for 5 consecutive days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo 250 mL IV for 5 consecutive days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.7",
                                            "spread": "11.60"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.5",
                                            "spread": "4.32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "5 weeks",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "GRF6019",
                    "description": "GRF6019 250 mL IV for 5 consecutive days",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 18,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 18,
                    "otherNumAffected": 8,
                    "otherNumAtRisk": 18
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Placebo 250 mL IV for 5 consecutive days",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 8,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 8,
                    "otherNumAffected": 3,
                    "otherNumAtRisk": 8
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Hypotension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Hypertension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Oedema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Injection site swelling",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Blood creatinine phosphokinase increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Blood pressure increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Sinus bradycardia",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                },
                {
                    "term": "Tooth extraction",
                    "organSystem": "Surgical and medical procedures",
                    "sourceVocabulary": "MedDRA 21.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 18
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI."
            },
            "pointOfContact": {
                "title": "Head of Communications",
                "organization": "Alkahest, Inc.",
                "email": "info@alkahest.com",
                "phone": "(650) 801-0474"
            }
        }
    },
    "target_category": "disease-targeted biologic",
    "drug": [
        "GRF6019 (human plasma protein fraction; plasma-derived biologic)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial description and title state this is a randomized, double-blind, placebo-controlled study of GRF6019 to assess safety, tolerability and potential cognitive benefit in subjects with severe Alzheimer\u2019s disease \u2014 i.e., an interventional therapeutic trial rather than a diagnostic or purely symptomatic assessment. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Act: GRF6019 is a plasma-derived product (a human plasma protein fraction) manufactured from pooled donor plasma and depleted of immunoglobulins and coagulation factors; it is a biologic (not a small molecule). Preclinical data reported effects on neurogenesis, synaptic density, reduced neuroinflammation and improved cognition in aged mice, motivating clinical testing in AD. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act (clinical evidence): GRF6019 has been tested in phase 2 studies (mild-to-moderate and a separate severe-AD trial). The severe-AD study was randomized and placebo-controlled; reported results emphasize safety/tolerability and stabilization or modest improvement on cognitive/functional endpoints, but were not powered for definitive efficacy. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Classification rationale \u2014 because GRF6019 is a biologic (plasma fraction) given IV with the intent to alter disease-related biology and cognitive/functional outcomes in AD, it best fits the 'disease-targeted biologic' category. Note ambiguity: GRF6019 is not a targeted monoclonal antibody against a single molecular hallmark (e.g., amyloid or tau) but is nevertheless a biologic therapy intended to modify brain aging/AD processes rather than solely acting as a symptomatic cognitive enhancer or a neuropsychiatric symptomatic treatment. The available trial registries and publications support this interpretation. \ue200cite\ue202turn0search0\ue202turn0search1\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: GRF6019 is a plasma\u2011derived biologic given IV with the intent to modify disease\u2011related biology in AD; preclinical and clinical reports describe effects on neurogenesis, synaptic density, and reduced neuroinflammation rather than a single-molecule target (e.g., not amyloid or tau). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: GRF6019 is a pooled human plasma protein fraction (depleted of clotting factors and immunoglobulins) and has been studied in randomized phase\u20112 trials in mild\u2011to\u2011moderate and severe AD where the emphasis was safety/tolerability and signal on cognition/structure. Proteomic analyses from treated patients show modulation of multiple pathways including complement/coagulation and neuronal pathways. Because the intervention appears to act on multiple biological pathways (neurogenesis, synaptic function, inflammation, complement/coagulation), the most specific CADRO fit is R) Multi\u2011target. \ue200cite\ue202turn0search1\ue202turn0search0\ue202turn0search6\ue201",
        "Reflect: Alternative single categories could include E) Neurogenesis, M) Synaptic Plasticity/Neuroprotection, or F) Inflammation given reported effects, but the published data indicate modulation of several distinct pathways rather than a single mechanism. Therefore 'R) Multi\u2011target' best captures the biological scope of GRF6019. The classification aligns with the trial being a disease\u2011targeted biologic with multimodal actions. \ue200cite\ue202turn0search3\ue202turn0search6\ue201",
        "Web search results (key sources cited above):",
        "- Hannestad et al., phase\u20112 severe AD randomized, double\u2011blind placebo\u2011controlled trial \u2014 safety/tolerability and stability on cognitive/functional endpoints. \ue200cite\ue202turn0search0\ue201",
        "- Hannestad et al., phase\u20112 mild\u2011to\u2011moderate AD trial (dose comparison) \u2014 safety/tolerability, cognitive stability over 24 weeks. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "- Lehallier et al., MRI analysis reporting slowed hippocampal atrophy with GRF6019 in mild\u2011to\u2011moderate AD. \ue200cite\ue202turn0search3\ue201",
        "- Alzforum summary of GRF6019 development, trial timeline and biology (plasma fraction; effects on synapses/neurogenesis; company/clinical context). \ue200cite\ue202turn0search4\ue201",
        "- Nanasi et al., deep plasma proteomics showing GRF6019 modulates complement/coagulation and neuronal pathways in treated AD patients. \ue200cite\ue202turn0search6\ue201"
    ]
}